ZLAB
HealthcareZai Lab Limited · Biotechnology · $2B
What is Zai Lab Limited?
Zai Lab is a Shanghai-based biopharmaceutical company focused on bringing innovative therapies to patients in Mainland China and Hong Kong across oncology, autoimmune, infectious disease, and neuroscience.
Zai Lab licenses, develops, and commercializes therapies — generating revenue through product sales of its approved medicines while advancing a broad clinical pipeline. The company partners with global innovators to bring differentiated treatments to the China market, spanning targeted cancer therapies, antibody-based treatments, and medical devices.
Founded in 2017 and headquartered in Shanghai, China.
- Zejula — PARP inhibitor for ovarian cancer
- Optune — tumor treating fields device for glioblastoma
- Qinlock — treatment for gastrointestinal stromal tumors
- Pipeline candidates targeting NSCLC, lymphoma, and gastric cancers
Is ZLAB a Good Stock to Buy?
UQS Score rates ZLAB as Below Average overall.
Growth stands out as the strongest pillar in Zai Lab's profile, reflecting the company's expanding commercial footprint and active late-stage pipeline. Risk is rated Neutral, suggesting the risk profile is not extreme relative to peers.
Quality and Moat are both rated Weak, pointing to limited profitability durability and competitive differentiation. Valuation is rated Elevated, which may give cost-conscious investors pause.
See the exact pillar breakdown and full financial metrics by signing up for a Pro membership at UQS Score. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does ZLAB pay dividends?
No — Zai Lab Limited does not currently pay a dividend.
Zai Lab does not currently pay a dividend. As a clinical-stage-leaning biopharmaceutical company, capital is directed toward pipeline development, regulatory approvals, and commercial expansion rather than shareholder distributions.
When does ZLAB report earnings?
Zai Lab reports earnings on a quarterly cadence, consistent with US-listed equities.
Revenue growth has been driven by expanding commercial product sales, though the company continues to invest heavily in its pipeline. Profitability remains a work in progress as R&D and commercialization costs weigh on near-term results.
For the most recent quarter's results, visit Zai Lab's investor relations page directly.
ZLAB Price History
-86.2% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Zai Lab Limited?
Based on Zai Lab Limited's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
Frequently Asked Questions
What does Zai Lab do?
Zai Lab develops and commercializes therapies for oncology, autoimmune disorders, infectious diseases, and neuroscience, primarily in Mainland China and Hong Kong. It partners with global pharmaceutical companies to license innovative treatments and bring them to the China market.
Does ZLAB pay dividends?
No, Zai Lab does not pay a dividend. The company reinvests available capital into its clinical pipeline and commercial operations, which is typical for growth-oriented biopharmaceutical companies at this stage.
When does ZLAB report earnings?
Zai Lab reports on a quarterly basis. For exact dates and the most recent results, check the investor relations section of Zai Lab's official website.
Is ZLAB a good stock to buy?
UQS Score rates ZLAB as Below Average overall. Growth is a relative strength, but Weak Quality and Moat scores alongside an Elevated Valuation rating suggest meaningful trade-offs. The full pillar breakdown is available to Pro members.
Is ZLAB overvalued?
UQS Score's Valuation pillar for ZLAB is rated Elevated, indicating the current price may reflect optimistic expectations relative to the company's fundamentals. Investors should weigh this against the Growth profile.
Is ZLAB a long-term quality investment?
From a long-term quality perspective, ZLAB's Weak Quality and Moat ratings indicate limited durability advantages today. The Strong Growth pillar shows pipeline momentum, but sustained quality improvements would strengthen the long-term case.
What is ZLAB's market cap bracket?
Zai Lab is classified as a mid-cap company. This places it in a segment that can offer growth potential but may carry more volatility than large- or mega-cap healthcare names.
What sector does ZLAB belong to?
Zai Lab operates in the Healthcare sector, specifically within biopharmaceuticals. Its focus spans oncology, autoimmune diseases, infectious diseases, and neuroscience, primarily serving patients in China.
Unlock Full ZLAB Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete UQS pillar score breakdown for ZLAB
- ✓Access detailed financial metrics and quality indicators
- ✓Compare ZLAB against sector peers on every pillar
- ✓Get the full analyst-style view available to Pro members
Pro Analysis
ZLAB — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 16, 2026 | 34.2 | 9.6 | 38.0 | 78.7 | 43.7 | 0.0 | -0.3 |
| May 11, 2026 | 34.5 | 9.6 | 38.0 | 80.1 | 43.7 | 0.0 | -0.6 |
| Apr 2, 2026 | 35.1 | 9.6 | 38.0 | 85.1 | 41.5 | 0.0 | — |
ZLAB — Pillar Breakdown
Quality
— 9.6/100 (25%)Zai Lab Limited currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 75.4/100 (20%)Zai Lab Limited is growing rapidly with strong revenue and earnings expansion.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 43.7/100 (15%)Zai Lab Limited has some risk factors including moderate leverage or solvency concerns.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Zai Lab Limited appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 38/100 (25%)Zai Lab Limited possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for ZLAB.
Score Composition
Financial Data
More Stock Analysis
How is the ZLAB UQS Score Calculated?
The UQS (Unified Quality Score) for Zai Lab Limited is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Zai Lab Limited's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Zai Lab Limited is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.